Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGY: Neoadjuvant DOS + Surgery vs Surgery in Gastric Cancer
NCT01515748Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2011
- Primary completion
- Jan 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, oxaliplatin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sanofi. Started Dec 2011; status: completed.
02
Drugs
docetaxeloxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01515748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515748.